Drug Approval | November 15, 2021
Zydus Cadila receives tentative approval for IBS tablets
The group now has 324 approvals and has so far filed over 400 ANDAs
The group now has 324 approvals and has so far filed over 400 ANDAs
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Acute therapies continue to report strong growth compared to chronic ones.
Pluss Advanced Technologies (PLUSS), has led the growth of energy storage materials across applications. Their proprietary Phase Change Material has gained wide acceptance in the pharmaceutical, logistics and food industries. The varied demands of the industry during Covid-19 has brought its technology into focus. Samit Jain, MD, PLUSS in conversation with Thomas C Thottathil discusses trends and outlines his plans for the business
Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Subscribe To Our Newsletter & Stay Updated
